Skip to main content
Hunan Warrant Pharmaceutical Co., Ltd. logo

Hunan Warrant Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 688799 ISIN · CNE100004P73 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 723 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688799

About Hunan Warrant Pharmaceutical Co., Ltd.

https://www.warrant.com.cn/

Hunan Warrant Pharmaceutical Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and distribution of chemical APIs and finished dosage forms. The company specializes in chiral drug technology and complex chemical synthesis, maintaining a robust portfolio that includes digestive system medications, cardiovascular treatments, and anti-infective agents. Key products include esomeprazole sodium and other high-end generic formulations. Warrant Pharmaceutical operates integrated R&D platforms and manufacturing facilities compliant with international quality standards, aiming to provide cost-effective therapeutic solutions. Its core competencies lie in the development of high-barrier generic drugs and the industrialization of advanced chiral synthesis processes, serving both domestic and international healthcare markets.

Recent filings

Filing Released Lang Actions
自愿披露关于获得药品注册证书的公告
Regulatory Filings Classification · 85% confidence The document is an announcement by Hunan Warner Pharmaceutical Co., Ltd. regarding receipt of a drug registration certificate from the National Medical Products Administration. It does not contain financial statements, voting results, management changes, or any other narrowly defined filing category. It is a general regulatory announcement about compliance/approval, fitting the “Regulatory Filings” (RNS) category.
2026-05-22 Chinese
自愿披露关于子公司通过药品GMP符合性检查的公告
Regulatory Filings Classification · 85% confidence The document is an official announcement by the company about its subsidiary passing a drug GMP compliance inspection issued by a regulatory authority. It contains no financial statements, management changes, voting results, or similar items. It is a general compliance/regulatory notice, fitting the fallback category for miscellaneous regulatory announcements. Therefore, it is classified as a Regulatory Filing (RNS).
2026-05-22 Chinese
2025年年度股东会会议材料
AGM Information Classification · 91% confidence The document is the full set of materials for the 2025 Annual General Meeting of Hunan Warner Pharmaceutical Co., including meeting notices, agenda items, proposals for shareholder approval, voting procedures, and related instructions. It is clearly the AGM meeting materials rather than an annual report or announcement of a report. This matches the AGM Information category.
2026-05-21 Chinese
关于2025年年度股东会变更会议召开地点的公告
Proxy Solicitation & Information Statement Classification · 82% confidence The document is an announcement of the 2025 annual shareholders meeting (AGM) for Hunan Huana Pharmaceutical, specifically notifying of a change in meeting location, providing the meeting agenda, voting proposals and the proxy authorization form. It is not the AGM materials themselves nor the voting results; rather it is information sent to shareholders to request votes and detail the meeting (including proxy solicitation). This matches the definition for Proxy Solicitation & Information Statement (PSI).
2026-05-21 Chinese
关于为全资孙公司提供担保的进展公告
Capital/Financing Update Classification · 82% confidence The document is an announcement detailing the progress of the company providing guarantees to its wholly owned subsidiary for borrowings from a bank, including board resolutions authorizing guarantee limits, contract signings, and termination agreements. This relates directly to the company’s financing arrangements. Therefore, it falls under Capital/Financing Update (CAP).
2026-05-13 Chinese
自愿披露关于子公司原料药获得上市申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the approval of a listing application for a pharmaceutical raw material by a regulatory authority (National Medical Products Administration). It details the approval notice, product information, and potential impact on the company. The document is short (909 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2026-05-07 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.